LGALS3BP is a novel and potential biomarker in clear cell renal cell carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

LGALS3BP is a novel and potential biomarker in clear cell renal cell carcinoma

Published:2024-02-22 Issue:4 Volume:16 Page:4033-4051
ISSN:1945-4589
Container-title:Aging
language:en
Short-container-title:Aging

Author:

Li Lei¹,Qin Sen²,Tan Hongwei³,Zhou Jiexue³

Affiliation:

1. Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China

2. Department of Orthopedics, The First People’s Hospital of Jingzhou, Jingzhou, Hubei, People’s Republic of China

3. Department of Organ Transplantation, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, People’s Republic of China

Publisher

Impact Journals, LLC

Reference46 articles.

1. Cancer statistics in China and United States, 2022: profiles, trends, and determinants.;Chen;Chin Med J (Engl),2022

2. Role of Autophagy in Renal Cancer.;Bai;J Cancer,2019

3. Adjuvant therapy in renal cell carcinoma.;Rini;Cancer,2019

4. Checkpoint inhibitor immunotherapy in kidney cancer.;McDermott;Nat Rev Urol,2020

5. Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target.;Sala;J Transl Med,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP